Development and evaluation of Hedyotis corymbosa (L.) extract containing phytosomes : a preclinical approach for treatment of neuropathic pain in rodent model
PURPOSE: The study was aimed to encapsulate Hedyotis corymbosa extract (HCE) into phytosomes to improve its therapeutic efficacy in neuropathic pain by enhancing the bioavailability of chief chemical constituent Hedycoryside -A (HCA).
METHODS: For preparing phytosomes complexes (F1, F2, and F3), HCE and phospholipids were reacted in disparate ratio. F2 was chosen to assess its therapeutic efficacy in neuropathic pain induced by partial sciatic nerve ligation. Nociceptive threshold and oral bioavailability were also estimated for F2.
RESULTS: Particle size, zeta potential and entrapment efficiency for F2 were analysed as 298.1 ± 1.1 nm, -3.92 ± 0.41 mV and 72.12 ± 0.72% respectively. F2 gave enhanced relative bioavailability (158.92%) of HCA along with a greater neuroprotective potential showing a significant antioxidant effect and augmentation (p < 0.05) in nociceptive threshold with the diminution in damage to nerves.
CONCLUSION: F2 is an optimistic formulation for enhancing the HCE delivery for the effective treatment of neuropathic pain.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Journal of microencapsulation - 40(2023), 3 vom: 28. Mai, Seite 186-196 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kumar, Nitin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4479-32-7 |
|---|
| Anmerkungen: |
Date Completed 10.04.2023 Date Revised 10.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/02652048.2023.2188938 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353860794 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353860794 | ||
| 003 | DE-627 | ||
| 005 | 20231226061000.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/02652048.2023.2188938 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353860794 | ||
| 035 | |a (NLM)36880280 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kumar, Nitin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development and evaluation of Hedyotis corymbosa (L.) extract containing phytosomes |b a preclinical approach for treatment of neuropathic pain in rodent model |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.04.2023 | ||
| 500 | |a Date Revised 10.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: The study was aimed to encapsulate Hedyotis corymbosa extract (HCE) into phytosomes to improve its therapeutic efficacy in neuropathic pain by enhancing the bioavailability of chief chemical constituent Hedycoryside -A (HCA) | ||
| 520 | |a METHODS: For preparing phytosomes complexes (F1, F2, and F3), HCE and phospholipids were reacted in disparate ratio. F2 was chosen to assess its therapeutic efficacy in neuropathic pain induced by partial sciatic nerve ligation. Nociceptive threshold and oral bioavailability were also estimated for F2 | ||
| 520 | |a RESULTS: Particle size, zeta potential and entrapment efficiency for F2 were analysed as 298.1 ± 1.1 nm, -3.92 ± 0.41 mV and 72.12 ± 0.72% respectively. F2 gave enhanced relative bioavailability (158.92%) of HCA along with a greater neuroprotective potential showing a significant antioxidant effect and augmentation (p < 0.05) in nociceptive threshold with the diminution in damage to nerves | ||
| 520 | |a CONCLUSION: F2 is an optimistic formulation for enhancing the HCE delivery for the effective treatment of neuropathic pain | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Hedycoryside | |
| 650 | 4 | |a Hedyotis corymbosa | |
| 650 | 4 | |a neuropathy | |
| 650 | 4 | |a neuroprotective | |
| 650 | 4 | |a phytosomes | |
| 650 | 7 | |a Phytosomes |2 NLM | |
| 650 | 7 | |a HCE |2 NLM | |
| 650 | 7 | |a 4479-32-7 |2 NLM | |
| 700 | 1 | |a Goel, Radha |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Neeraj Kant |e verfasserin |4 aut | |
| 700 | 1 | |a Gaur, Praveen Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Pradeep Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microencapsulation |d 1989 |g 40(2023), 3 vom: 28. Mai, Seite 186-196 |w (DE-627)NLM013098217 |x 1464-5246 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:3 |g day:28 |g month:05 |g pages:186-196 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/02652048.2023.2188938 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 3 |b 28 |c 05 |h 186-196 | ||